Market Overview

UPDATE: Credit Suisse Initiates Cubist Pharmaceuticals at Neutral; Expecting Positive Readouts

Related CBST
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog

Credit Suisse initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Neutral rating and a $52.00 price target.

Credit Suisse analyst Jason Kantor commented, "We expect that positive CXA-201 data in H2:13 will increase confidence in the long-term sustainability of CBST's antibiotic franchise and lay the ground work for global expansion. Data from a recently optioned Phase II asset will also read out in the same timeframe. Near-term expenses and cash outlays may limit near-term upside."

Cubist Pharmaceuticals closed at $47.47 on Thursday.

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (CBST)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free